ERBB2 and breast cancer: No differences in pre- and post-NACT hormonal receptor expression have been observed in non-luminal HER2+ BC as it might be expected, due to anti-proliferative therapy effect, post-NACT ki67 expression underwent a significant reduction (P < 0.001) (SI Table 2).